For hardly the first time in recent days, investors have become excited about the prospect of a significant change in U.S. drug laws.Will he or won't he? This is the question that's been front of mind for many marijuana stock investors over the past few days, as both credible media reports and President Trump himself fueled speculation that he will begin the process of decriminalizing the drug. Comments from the President late Monday injected new bullishness into weed stocks the following day. Sector mainst ...

The legal status of marijuana in the U.S. remains scattered and confusing.A sharp pull-back in marijuana stocks dinged the value of Tilray Brands (TLRY 10.04%) shares on Monday. At the end of last week, investor hopes rose that President Donald Trump would take an important step toward the de facto legalization of the drug, but those hopes didn't materialize on Monday. Investors eagerly sold out of Tilray, leaving the stock with a 10% loss that trading session. Awaiting a signaturePot stock bulls came out i ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

If weed becomes legal, will Aurora Cannabis become profitable?Aurora Cannabis (ACB +15.38%) stock leapt 14.5% "higher" (get it? Marijuana? High?) through 11:55 a.m. ET Friday on some positive marijuana news out of the White House.As The Washington Post reports, President Trump wants to legalize marijuana (sort of), and marijuana investors are overjoyed at the prospect. President Trump's Christmas gift to marijuana investorsThe Post cites six separate sources confirming that Trump will issue an executive or ...

Key Points Reports indicate the President will instruct federal agencies to make marijuana a Schedule III drug soon. This isn't "legalization" per se, but it will make marijuana a bit more "legal." 10 stocks we like better than Tilray Brands › Tilray Brands (NASDAQ: TLRY) stock went up like a rocket this morning, soaring 25% through 10:15 a.m. ET -- and the stock was up even more in the very early morning. You can thank President Trump for the gains -- because according to The Washington Post, he's ...

Marijuana stocks spun higher before Friday's stock market, rallying on reports President Donald Trump aims to loosen federal restrictions on marijuana, Plans call for cutting oversight of marijuana products to the same level as some ordinary prescription painkillers. The Washington Post, citing six people familiar with the discussions, reported Thursday that Trump has discussed plans with House Speaker Mike Johnson.… ...

Core Insights - The U.S. cannabis industry is evolving with strong long-term growth expectations despite recent sector pullbacks, leading investors to seek companies with real revenue and disciplined expansion plans [1][2][20] Industry Overview - Legalization progress is expected to continue into 2026 and 2027, with state-level expansion and adult-use markets growing rapidly [2] - Large operators with broad footprints are benefiting from rising demand as many states have legalized recreational use [2] Company Highlights - **Trulieve Cannabis Corp. (TCNNF)**: - Holds a strong leadership position in Florida with over 190 dispensaries, focusing on medical patients and gradually expanding into other states [4][5] - Financially, Trulieve shows strong revenue performance and has improved profit margins through cost management and operational efficiency [7][8][9] - **Curaleaf Holdings, Inc. (CURLF)**: - One of the largest cannabis operators in the U.S. with over 140 dispensaries and a diversified product portfolio [10][11] - Continues to manage debt and strengthen its balance sheet while focusing on expense reductions and operational efficiency [13][14] - **Green Thumb Industries Inc. (GTBIF)**: - Operates over 90 stores with a focus on branded consumer products and product innovation [15][16] - Demonstrates impressive revenue growth and strong gross margins, maintaining a disciplined approach to expansion [18][19] Financial Performance - Trulieve has reported steady quarterly revenue during 2025, with a focus on debt reduction and cash flow improvements [7][9] - Curaleaf remains a top revenue producer but faces profitability challenges, emphasizing margin improvements [13][14] - Green Thumb has shown consistent quarterly revenue increases and strong financial profiles, making it an attractive long-term investment [18][19]

Industry Overview - The U.S. cannabis industry is projected to exceed $45 billion by 2025, driven by strong consumer demand and expanding state-level access [1] - The sector supports over 400,000 full-time jobs and contributes billions in tax revenue annually [1] - Recent developments indicate potential federal government reclassification, enhancing optimism among investors [1] Company Highlights Trulieve Cannabis Corp. (TCNNF) - Trulieve operates over 190 dispensaries across 11 states, with a strong presence in Florida, Pennsylvania, and Arizona [3] - The company reported revenue near $290 million in Q2 2025, with a gross profit margin of approximately 50% [6] - Trulieve's net income improved year-over-year, and it reduced long-term debt, strengthening its balance sheet [6] Curaleaf Holdings, Inc. (CURLF) - Curaleaf operates in over 17 states with more than 150 dispensaries, primarily in Florida [7] - The company reported revenue of roughly $310 million, maintaining a gross margin near 50% [9] - Curaleaf narrowed its net losses and focused on high-performing states and premium product categories [9] Green Thumb Industries Inc. (GTBIF) - Green Thumb operates more than 90 dispensaries across 15 states, with significant retail strength in Illinois, Pennsylvania, and Florida [10] - The company achieved nearly $305 million in revenue, with gross margins around 52% [11] - Green Thumb improved its net income year-over-year and maintained a solid cash position for reinvestment [11] Market Sentiment - Investors are closely monitoring U.S. marijuana stocks as industry sentiment improves and market catalysts align [1][2] - Traders are employing technical and fundamental analysis to navigate the volatile cannabis market effectively [2]

Core Insights - Tilray Brands (NASDAQ: TLRY) stock surged over 60% following President Donald Trump's video advocating for marijuana legalization for senior citizens, with potential Medicare coverage [1] - The stock experienced some pullback as momentum traders took profits, but rebounded with a 5.6% increase on Thursday [1] Group 1: Company Developments - Tilray is expanding its production of premium "Tilray Craft" cannabis in Germany, introducing five new cannabis flower products aimed at the medical marijuana market [3] - Currently, Tilray's European market is more significant than its U.S. market, with EMEA revenues exceeding $323 million annually compared to less than $274 million in the U.S. [5] Group 2: Financial Performance - Over the past year, Tilray has lost $2.2 billion, and its current market capitalization stands at approximately $2.2 billion [6] - Despite positive developments in production and potential market expansion, Tilray continues to face substantial financial losses [7]

Core Viewpoint - Curaleaf Holdings experienced a significant stock price fluctuation, with a 37% increase followed by a 5.9% decline, attributed to profit-taking by momentum traders after a successful trading day [1][4]. Group 1: Stock Performance - Curaleaf's stock price rose sharply by 37% after a pro-marijuana video posted by President Trump on Truth Social, which advocated for Medicare coverage of medical marijuana [3][8]. - Following the spike, the stock retreated by 5.9% as traders took profits, but there was no new negative news to justify the decline [1][4]. Group 2: Valuation Concerns - Curaleaf's current valuation is high, trading at nearly 50 times its trailing free cash flow of $50 million, raising concerns about whether the stock price is justified given the uncertainty surrounding marijuana legalization efforts [6]. - The stock's recent price increase may not be sustainable based on a single social media post, suggesting caution for potential investors [5][6]. Group 3: Investment Recommendations - Analysts suggest that selling Curaleaf stock may not be a bad idea given its recent price surge, as it is now 37% higher than just 24 hours prior [5][8]. - Curaleaf was not included in a list of the top 10 stocks recommended by The Motley Fool Stock Advisor, indicating that there may be better investment opportunities available [9].